6th Floor 230 Third Avenue
Waltham, MA 02451
844 531 1834
Full Time Employees: 19
|Mr. Marc M. P. de Garidel||CEO & Director||776.86k||N/A||1958|
|Dr. Mason W. Freeman M.D.||Chief Medical Officer||285.56k||N/A||1951|
|Ms. Catherine Pearce DHSc, M.B.A., MBA||Co-Founder & COO||N/A||N/A||1976|
|Mr. Michael W. Kalb CPA||Exec. VP, CFO & Principal Accounting Officer||N/A||N/A||1971|
|Ms. Ida Hatoum||Sr. VP and Head of People, Talent & Culture||N/A||N/A||N/A|
|Hema Keshava||Corp. Controller||N/A||N/A||N/A|
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.
CinCor Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.